Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Melanin Concentrating Hormone Receptor 1 Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 1:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Pipeline Review, H2 2016’, provides in depth analysis on Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted pipeline therapeutics.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693287-melanin-concentrating-hormone-receptor-review-h2-2016

The report provides comprehensive information on the Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics development and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) 
- The report reviews Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693287-melanin-concentrating-hormone-receptor-review-h2-2016         

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Report Coverage 5 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) Overview 6 
Therapeutics Development 7 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Products under Development by Stage of Development 7
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Products under Development by Therapy Area 8 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Products under Development by Indication 9 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Pipeline Products Glance 10 
Early Stage Products 10 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Products under Development by Companies 11 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Therapeutics Assessment 13 
Assessment by Monotherapy/Combination Products 13 
Assessment by Mechanism of Action 14 
Assessment by Route of Administration 15 
Assessment by Molecule Type 16 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Companies Involved in Therapeutics Development 17 
AstraZeneca Plc 18 
Boehringer Ingelheim GmbH 19 
LEO Pharma A/S 20 
Takeda Pharmaceutical Company Limited 21 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Drug Profiles 22 
ALB-127158(a) – Drug Profile 22 
Product Description 22 
Mechanism Of Action 22 
R&D Progress 22 
AZ-13483342 – Drug Profile 24 
Product Description 24 
Mechanism Of Action 24 
R&D Progress 24 
AZD-3857 – Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
BI-186908 – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
Small Molecule to Antagonize MCHR1 for Obesity – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
Small Molecules to Antagonize MCHR1 for Weight Loss – Drug Profile 28 
Product Description 28 
Mechanism Of Action 28 
R&D Progress 28 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Dormant Projects 29 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Discontinued Products 30 
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) – Featured News & Press Releases 31 
Oct 03, 2011: AMRI Presents Final Phase I Clinical Studies Results Of Obesity Compound At 29th Annual Scientific Meeting Of Obesity Society 31 
May 31, 2011: AMRI Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound 31 
May 19, 2011: AMRI To Present Phase I Clinical Results Of Obesity Compound At European Congress On Obesity 32 
Jul 21, 2010: AMRI Initiates Phase I Study Of ALB-127158(a) For Treatment Of Obesity 32 
Jun 02, 2009: AMRI Advances New Obesity Drug MCH-1 Receptor Antagonist Toward IND Submission 33 
Appendix 35 
Methodology 35 
Coverage 35 
Secondary Research 35 
Primary Research 35 
Expert Panel Validation 35 
Contact Us 35 
Disclaimer 36

List of Tables 
Number of Products under Development for, H2 2016 7 
Number of Products under Development by Therapy Area, H2 2016 8 
Number of Products under Development by Indication, H2 2016 9 
Comparative Analysis by Early Stage Products, H2 2016 10 
Number of Products under Development by Companies, H2 2016 11 
Products under Development by Companies, H2 2016 12 
Assessment by Monotherapy/Combination Products, H2 2016 13 
Number of Products by Stage and Mechanism of Action, H2 2016 14 
Number of Products by Stage and Route of Administration, H2 2016 15 
Number of Products by Stage and Molecule Type, H2 2016 16 
Pipeline by Albany Molecular Research, Inc., H2 2016 17 
Pipeline by AstraZeneca Plc, H2 2016 18 
Pipeline by Boehringer Ingelheim GmbH, H2 2016 19 
Pipeline by LEO Pharma A/S, H2 2016 20 
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 21 
Dormant Projects, H2 2016 29 
Discontinued Products, H2 2016 30

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693287

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.